Stocks · News reference
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Penumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.
BrightSpring Health Services (BTSG) is rated a Strong Buy with strong momentum in Provider Services and expanding specialty pharmacy and infusion operations. However, the company faces near-term margin pressure from Inflation Reduction Act reimbursement cuts and execution risks from multiple integrations and geographic expansions through 2026.
Resmed is divesting its MatrixCare business for $490 million to streamline its Residential Care Software segment and focus on higher-growth platforms. The company's Masks segment showed strong 13% revenue growth in fiscal 2026, driven by product innovation and improved compliance rates. However, macroeconomic pressures and intense competition pose operational risks.